Back to top

Analyst Blog

BIND Therapeutics, Inc. (BIND - Snapshot Report) announced the completion of its one and a half year old agreement with Amgen Inc. (AMGN - Analyst Report). In Jan 2013, the two companies had entered into a one-year collaboration agreement to optimize a specific therapeutic payload from Amgen, which was later extended by another six months to complete the research plan.

BIND Therapeutics and Amgen collaborated to develop a nanomedicine for treating solid cancer tumors utilizing BIND’s platform for targeted and programmable nanomedicines and Amgen’s unrevealed proprietary cancer compound. Moreover, BIND Therapeutics held rights to get a license from Amgen for the development, manufacture and commercialization of Accurins (the former’s programmable therapeutics) containing Amgen’s therapeutic payload if Amgen failed to exercise its option.

BIND Therapeutics notified that results from the research were not convincing enough to proceed forward. Following the completion of the agreement the companies will not exercise their options to develop an Accurin incorporating the Amgen therapeutic payload.

The news comes as a huge disappointment for the company. Although BIND Therapeutics mentioned that it will continue to develop its Accurin platform, we expect the shares of the company to go down significantly on the news.

BIND Therapeutics still has collaboration agreements with companies like AstraZeneca (AZN - Analyst Report) to develop Accurins based on therapeutic payloads. Termination or failure of those agreements will be damaging for the stock.

The lead pipeline candidate at BIND Therapeutics is BIND-014, an Accurin. The candidate is undergoing phase II studies for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer.

BIND Therapeutics presently carries a Zacks Rank #4 (Sell). The Medicines Company (MDCO - Analyst Report) is a better-ranked stock with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%